Tandem Diabetes Care Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

On Thursday, Tandem Diabetes Care (TNDM) stock earned a positive adjustment to its Relative Strength (RS) Rating, from 79 to 82.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock’s price performance over the last 52 weeks matches up against that of all other stocks.

Over 100 years of market history shows that the market’s biggest winners often have an 80 or higher RS Rating as they begin their biggest runs.

Looking For Winning Stocks? Try This Simple Routine

Is Tandem Diabetes Care Stock A Buy?

The IBD 50 stock has climbed more than 5% past a 113.58 entry in a first-stage cup with handle, meaning it’s now out of a proper buy zone. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips. Also, check out “Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks.”

Top and bottom line growth moved higher last quarter. Earnings were up 113%, compared to 0% in the prior report. Revenue increased from 44% to 58%.

Solid Earnings, Revenue Growth

Tandem Diabetes Care stock holds the No. 34 rank among its peers in the Medical-Products industry group. Bio Rad Labs (BIOB) and Semler Scientific (SMLR) are also among the group’s highest-rated stocks.


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Most Related Links :
usnewsmail Governmental News Finance News

Source link

Back to top button